KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Accumulated Expenses: 2010-2015

Historic Other Accumulated Expenses for Biomarin Pharmaceutical (BMRN) over the last 4 years, with Jun 2015 value amounting to $9.5 million.

  • Biomarin Pharmaceutical's Other Accumulated Expenses rose 161.81% to $9.5 million in Q2 2015 from the same period last year, while for Jun 2015 it was $9.5 million, marking a year-over-year increase of 161.81%. This contributed to the annual value of $8.2 million for FY2014, which is 69.11% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Other Accumulated Expenses of $9.5 million as of Q2 2015, which was up 8.70% from $8.7 million recorded in Q1 2015.
  • Biomarin Pharmaceutical's Other Accumulated Expenses' 5-year high stood at $13.3 million during Q1 2012, with a 5-year trough of $1.4 million in Q2 2013.
  • In the last 3 years, Biomarin Pharmaceutical's Other Accumulated Expenses had a median value of $4.3 million in 2013 and averaged $5.1 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Other Accumulated Expenses crashed by 81.46% in 2013, and later skyrocketed by 165.66% in 2014.
  • Over the past 5 years, Biomarin Pharmaceutical's Other Accumulated Expenses (Quarterly) stood at $9.3 million in 2011, then slumped by 33.26% to $6.2 million in 2012, then decreased by 21.10% to $4.9 million in 2013, then surged by 69.11% to $8.2 million in 2014, then skyrocketed by 161.81% to $9.5 million in 2015.
  • Its Other Accumulated Expenses was $9.5 million in Q2 2015, compared to $8.7 million in Q1 2015 and $8.2 million in Q4 2014.